How should I manage a patient with fasting triglycerides of 320 mg/dL and HDL cholesterol of 35 mg/dL?

Management of Triglycerides 320 mg/dL and HDL 35 mg/dL

Start a high-intensity statin immediately as first-line therapy, aggressively pursue lifestyle modifications (weight loss, alcohol cessation, reduced carbohydrate intake), and consider adding icosapent ethyl if the patient has established cardiovascular disease or diabetes with additional risk factors once triglycerides remain >150 mg/dL on statin therapy. 1, 2

Initial Assessment and Risk Stratification

Your patient has moderate hypertriglyceridemia (320 mg/dL falls in the 200-499 mg/dL range) combined with low HDL cholesterol (<40 mg/dL), representing classic atherogenic dyslipidemia that significantly increases cardiovascular risk 3, 4. This lipid pattern is particularly concerning because:

• The primary risk here is atherosclerotic cardiovascular disease (ASCVD), not pancreatitis (which becomes the dominant concern only when triglycerides exceed 500 mg/dL, and especially >1000 mg/dL) 1, 4
• Low HDL combined with elevated triglycerides creates a high-risk metabolic profile
• You must calculate non-HDL cholesterol (total cholesterol minus HDL) as a secondary target, which should be <130 mg/dL 1, 5

Critical first steps:

• Obtain a complete fasting lipid panel if not already done
• Screen for secondary causes: uncontrolled diabetes, hypothyroidism, chronic kidney disease, medications (thiazides, beta-blockers, estrogens, corticosteroids, protease inhibitors)
• Assess for metabolic syndrome components
• Determine if patient has established ASCVD or diabetes 1, 4

Lifestyle Interventions (Foundation of Therapy)

These are non-negotiable and must be implemented aggressively 3, 1, 6:

Dietary modifications:

• Reduce saturated fat to <7% of total calories
• Eliminate trans fats completely
• Reduce cholesterol intake to <200 mg/day
• Critically important: Reduce simple carbohydrates and added sugars/fructose—this can lower triglycerides by 10-20% 6
• Complete alcohol abstinence—alcohol significantly raises triglycerides 3, 6
• Increase omega-3 fatty acids from fish

Weight and activity:

• Target 5-10% weight loss (expect 20% triglyceride reduction) 6
• 30-60 minutes of moderate aerobic activity most days of the week 7

Realistic expectation: Intensive lifestyle changes can reduce triglycerides by 50% or more when fully implemented 6. However, most patients require pharmacotherapy in addition.

Pharmacologic Management Algorithm

Step 1: Initiate Statin Therapy (First-Line)

Start a high-intensity statin immediately 1, 2, 8:

• Atorvastatin 40-80 mg daily, OR
• Rosuvastatin 20-40 mg daily

Rationale:

• Statins are the only lipid-lowering therapy with robust cardiovascular outcome data in this population 1, 9
• High-dose statins provide moderate triglyceride reduction (typically 20-30%) in addition to LDL lowering 3
• The 2020 Endocrine Society guideline explicitly recommends statins as first-line for patients with diabetes and cardiovascular risk factors 1
• Target LDL-C <70 mg/dL if high cardiovascular risk, <100 mg/dL otherwise 1, 7

Step 2: Optimize Glycemic Control (If Diabetic)

If the patient has diabetes, this is crucial 3:

• Improved glycemic control can be "very effective" for reducing triglycerides 3
• Insulin therapy (alone or with insulin sensitizers) is particularly effective for triglyceride lowering 3
• Optimize diabetes management before adding additional lipid medications

Step 3: Consider Adding Icosapent Ethyl (If Criteria Met)

Add icosapent ethyl 4 grams daily if ALL of the following apply 1, 2, 10:

1. Patient is on maximally tolerated statin therapy
2. Triglycerides remain >150 mg/dL (ideally 150-499 mg/dL)
3. Patient has EITHER:
   • Established ASCVD, OR
   • Diabetes PLUS ≥2 additional cardiovascular risk factors

This recommendation is based on the REDUCE-IT trial, which showed significant cardiovascular benefit with icosapent ethyl in this specific population 1, 10. This is a Class 2B recommendation (may be considered), not mandatory, but represents the strongest evidence for additional triglyceride-directed therapy beyond statins.

What NOT to Do (Common Pitfalls)

Avoid fibrate monotherapy in diabetic patients with undesirable triglyceride levels 3. If fibrates are used, they should be added to statin therapy, not used alone.

Statin-fibrate combination therapy:

• Has not been shown to improve cardiovascular outcomes and is generally not recommended 2
• If combination therapy is absolutely necessary, use fenofibrate (not gemfibrozil) with a statin to minimize myositis risk 3, 9, 3
• Gemfibrozil specifically increases statin levels and carries higher myositis risk 9

Niacin:

• Statin plus niacin has not shown cardiovascular benefit and may increase stroke risk 2
• Generally not recommended despite its ability to raise HDL 2
• If used in diabetics, keep doses modest (≤2 g/day) and monitor glucose closely 3

Do not target HDL cholesterol pharmacologically—while low HDL predicts risk, therapies aimed at raising HDL have failed to show cardiovascular benefit 2, 11

Monitoring Strategy

• Recheck fasting lipid panel 4-6 weeks after initiating or changing therapy 12
• Monitor for statin side effects (muscle symptoms, liver enzymes)
• If using combination therapy, monitor creatine kinase for myositis risk
• Reassess cardiovascular risk factors at each visit
• Continue emphasizing lifestyle modifications at every encounter

Special Considerations

If triglycerides were to rise to ≥500 mg/dL: The treatment paradigm shifts—preventing pancreatitis becomes the primary goal, and you would need to add fibrate or high-dose omega-3 therapy urgently, potentially before optimizing LDL 1, 4

Calculate and monitor non-HDL cholesterol: This is particularly important in hypertriglyceridemia because LDL-C may underestimate atherogenic particle burden. Target non-HDL-C <130 mg/dL (or <100 mg/dL for very high-risk patients) 1, 5, 7

The evidence base is evolving: The 2026 ACC/AHA guideline 8, 13 emphasizes that triglyceride-rich lipoproteins contribute to ASCVD risk and supports risk-based pharmacologic interventions, but the core approach remains: lifestyle first, statins as foundation, selective use of additional agents in high-risk patients with persistent elevation.